Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Present with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild-to-moderate AD~* Men or nonfertile women, at least 50 years of age. Nonfertile is defined as hysterectomy and/or bilateral oophorectomy, or amenorrhea for at least 1 year~* Have up to 2 partners who will provide a separate written informed consent to participate~* Have adequate vision and hearing for neuropsychological testing in the opinion of the investigator~* Positive florbetapir scan~Exclusion Criteria:~* Do not have up to 2 reliable partners who are in frequent contact with the participant, who will accompany the participant to the office and/or be available by telephone at designated times, and will monitor administration of prescribed medications~* Are being monitored for radiation due to occupational exposure to ionized radiation, or exposure to ionizing radiation within last 12 months from an investigational study~* History of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous malformation, or carotid artery occlusion, or stroke or epilepsy~* Have any contraindications for magnetic resonance imaging (MRI) studies, including claustrophobia, the presence of contraindicated metal (ferromagnetic) implants, cardiac pacemaker~* Have allergies to humanized monoclonal antibodies, including proteins and diphenhydramine, epinephrine, and methylprednisolone~* Have gamma globulin therapy within the last year~* Previously dosed in any other study investigating active immunization against amyloid beta (Aβ)~* Previously dosed in any other study investigating passive immunization against Aβ within the last 6 months~* Have current serious or unstable illnesses

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: Placebo Single Dose (SD) (Type: PLACEBO_COMPARATOR): Participants received single intravenous (IV) dose of placebo.
- Part A: 10 Milligram Per Kilogram (mg/kg) LY3002813 SD (Type: EXPERIMENTAL): Participants received single IV dose of 10 mg/kg LY3002813.
- Part A: 20 mg/kg LY3002813 SD (Type: EXPERIMENTAL): Participants received single IV dose of 20 mg/kg LY3002813.
- Part A: 40 mg/kg LY3002813 SD (Type: EXPERIMENTAL): Participants received single IV dose of 40 mg/kg LY3002813.
- Part B: Placebo Q2W (Type: PLACEBO_COMPARATOR): Participants received multiple IV dose of placebo every 2 weeks (Q2W) for 24 weeks.
- Part B: 10 mg/kg LY3002813 Q2W (Type: EXPERIMENTAL): Participants received multiple IV dose of 10 mg/kg LY3002813 Q2W for 24 weeks.
- Part C: Placebo Q4W (Type: PLACEBO_COMPARATOR): Participants received multiple IV dose of placebo every 4 weeks (Q4W) for 72 weeks.
- Part C:10 mg/kg LY3002813 Q4W (Type: EXPERIMENTAL): Participants received multiple IV dose of 10 mg/kg LY3002813 Q4W for 72 weeks.
- Part C:20 mg/kg LY3002813 Q4W (Type: EXPERIMENTAL): Participants received multiple IV dose of 20 mg/kg LY3002813 Q4W for 72 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).